EUVIMEDScopri EUVIMED
MetaanalyseÜbersichtsarbeit

Efficacy, Safety, and Net Clinical Benefit of Post‐Atrial Fibrillation Ablation Anticoagulation

Mustafa Abomohsen iD, Ahmed Elmorsy Mohamed iD, Abdul Hakim Almakadma, Azad Mojahedi, Zeyad Kholeif, Aya Elalfy, Mahmoud Shams, Ahmed Farid Gadelmawla iD, Imad Samman Tahhan iD, Mohab Elnashar, Rana Rashwan, Mohamed Elnady and 1 more

Pacing and Clinical Electrophysiology · 2026-05 · 49 (5) · 590-601

DOI: 10.1111/pace.70224 ↗

At a glance

Metaanalyse in Pacing and Clinical Electrophysiology, published online on 2026-03-26. Written by Mustafa Abomohsen and 12 co-authors. Institution: Department of Internal Medicine, Brookdale University Hospital, Brooklyn, New York, USA. Major MEDLINE topics: Atrial Fibrillation, Catheter Ablation, Anticoagulants, Thromboembolism. Cited 1 times so far (Crossref); 25 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

The optimal long‐term antithrombotic strategy after apparently successful catheter ablation of atrial fibrillation (AF) remains uncertain, particularly in patients who meet conventional guideline thresholds for oral anticoagulation (OAC).

Objectives

To compare continuation versus cessation strategies of long‐term OAC after successful AF ablation and to quantify net clinical benefit (NCB) integrating thromboembolic and bleeding outcomes.

Methods

We searched PubMed, Cochrane CENTRAL, and Embase from inception through February 2026 for randomized and comparative observational studies evaluating long‐term OAC continuation versus cessation (no OAC and/or switch to aspirin) after successful AF ablation. Risk of bias was assessed using RoB2 for randomized trials and a modified Newcastle–Ottawa Scale (NOS) for observational studies. Random‐effects meta‐analyses used a restricted maximum likelihood estimator with Hartung–Knapp adjustment. NCB was calculated as: thromboembolic event rate − (1.5 × major bleeding rate).

Results

Six studies met the inclusion criteria (four randomized trials and two observational cohorts). Stroke/transient ischemic attack (TIA) events were reported in six studies and were not significantly different between OAC continuation and cessation strategies (OR 0.69; 95% CI 0.24–1.99; p = 0.49). Systemic embolism (three studies) did not differ between groups ( p = 0.12). Major bleeding (five studies) was numerically higher with continued OAC but not statistically significant (OR 2.07; 95% CI 0.88–4.86; p = 0.09). In NCB analysis, continued OAC yielded more negative or near‐neutral NCB values, whereas, the cessation strategies were less negative or marginally positive; the fixed‐effect risk difference in NCB (continued OAC vs cessation) was +0.00067 (95% CI −0.00279 to +0.00413).

Conclusion

This meta‐analysis suggests that after successful AF ablation, continuing OAC does not significantly reduce stroke risk compared to cessation or switching to aspirin, but it may increase major bleeding. While NCB trends favor cessation, the low absolute event rates and the risk of silent AF recurrence necessitate caution.

Subjects

MeSH terms (MEDLINE)

Atrial FibrillationCatheter AblationAnticoagulantsThromboembolismHumansTreatment OutcomeStrokeHemorrhage

Author keywords

ablationanticoagulationaspirinatrial atrial fibrillationcontinued DOACdirect oral anticoagulantsnet clinical benefittherapy cessation

Substances

Anticoagulants

Authors and institutions

  • Department of Internal Medicine, Brookdale University Hospital, Brooklyn, New York, USA.
  • Department of Internal Medicine, Baptist Hospitals of Southeast Texas, Beaumont, Texas, USA.
  • Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA.
  • Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Faculty of Medicine, Menoufia University, Menoufia, Egypt.
  • Department of Internal Medicine, Wellington Regional Medical Center, Wellington, Florida, USA.

ORCID profiles: Mustafa Abomohsen, Ahmed Elmorsy Mohamed, Ahmed Farid Gadelmawla, Imad Samman Tahhan

Cite

APA

Abomohsen, M., Mohamed, A. E., Almakadma, A. H., Mojahedi, A., Kholeif, Z., Elalfy, A., Shams, M., Gadelmawla, A. F., Tahhan, I. S., Elnashar, M., Rashwan, R., Elnady, M., & Gunsburg, M. (2026). Efficacy, Safety, and Net Clinical Benefit of Post‐Atrial Fibrillation Ablation Anticoagulation. Pacing and Clinical Electrophysiology, 49(5), 590-601. https://doi.org/10.1111/pace.70224

Vancouver

Abomohsen M, Mohamed AE, Almakadma AH, Mojahedi A, Kholeif Z, Elalfy A, et al. Efficacy, Safety, and Net Clinical Benefit of Post‐Atrial Fibrillation Ablation Anticoagulation. Pacing and Clinical Electrophysiology. 2026;49(5):590-601. doi:10.1111/pace.70224

BibTeX
@article{Abomohsen2026,
  author = {Abomohsen, Mustafa and Mohamed, Ahmed Elmorsy and Almakadma, Abdul Hakim and Mojahedi, Azad and Kholeif, Zeyad and Elalfy, Aya and Shams, Mahmoud and Gadelmawla, Ahmed Farid and Tahhan, Imad Samman and Elnashar, Mohab and Rashwan, Rana and Elnady, Mohamed and Gunsburg, Moshe},
  title = {Efficacy, Safety, and Net Clinical Benefit of Post‐Atrial Fibrillation Ablation Anticoagulation},
  journal = {Pacing and Clinical Electrophysiology},
  year = {2026},
  volume = {49},
  number = {5},
  pages = {590--601},
  doi = {10.1111/pace.70224}
}
Start for free →